<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardio</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиология</journal-title><trans-title-group xml:lang="en"><trans-title>Kardiologiia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0022-9040</issn><issn pub-type="epub">2412-5660</issn><publisher><publisher-name>Kardiomag</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18087/cardio.2622</article-id><article-id custom-type="elpub" pub-id-type="custom">cardio-648</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>RESEARCH ARTICLES</subject></subj-group></article-categories><title-group><article-title>Прогноз жизни пациентов с хронической сердечной недостаточностью и фибрилляцией предсердий в зависимости от контроля гемодинамических показателей и толерантности к физической нагрузке на фоне базисной терапии</article-title><trans-title-group xml:lang="en"><trans-title>Prognosis of the life of patients with chronic heart failure and atrial fibrilla-tion, depending on the control of hemodynamic parameters and tolerance to physical exertion in the background of basic therapy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Виноградова</surname><given-names>Н. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Vinogradova</surname><given-names>N. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>603950, Нижний Новгород, пл. Минина и Пожарского, д. 10/1, </p><p>603000, Н. Новгород, ул. Чернышевского д. 22</p></bio><bio xml:lang="en"><p>Minin and Pozharsky square 10/1, Nizhny Novgorod 603950, </p><p>Chernyshevskogo 22, Nizhny Novgorod 603000 </p></bio><email xlink:type="simple">vinogradovang@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Поляков</surname><given-names>Д. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Polyakov</surname><given-names>D. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>603950, Нижний Новгород, пл. Минина и Пожарского, д. 10/1</p></bio><bio xml:lang="en"><p>Minin and Pozharsky square 10/1, Nizhny Novgorod 603950</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фомин</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Fomin</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>603950, Нижний Новгород, пл. Минина и Пожарского, д. 10/1</p></bio><bio xml:lang="en"><p>Minin and Pozharsky square 10/1, Nizhny Novgorod 603950</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жиркова</surname><given-names>М. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhirkova</surname><given-names>M. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>603000, Н. Новгород, ул. Чернышевского д. 22</p></bio><bio xml:lang="en"><p>Chernyshevskogo 22, Nizhny Novgorod 603000 </p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «ПИМУ» МЗ РФ;&#13;
ГБУЗ НО «ГКБ №38»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Privolzhsky Research Medical University;&#13;
Municipal Clinical Hospital #38</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «ПИМУ» МЗ РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Privolzhsky Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ГБУЗ НО «ГКБ №38»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Municipal Clinical Hospital #38</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>24</day><month>05</month><year>2019</year></pub-date><volume>59</volume><issue>4S</issue><fpage>51</fpage><lpage>58</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Kardiomag, 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Kardiomag</copyright-holder><copyright-holder xml:lang="en">Kardiomag</copyright-holder><license xlink:href="https://cardio.elpub.ru/jour/about/submissions#copyrightNotice" xlink:type="simple"><license-p>https://cardio.elpub.ru/jour/about/submissions#copyrightNotice</license-p></license></permissions><self-uri xlink:href="https://cardio.elpub.ru/jour/article/view/648">https://cardio.elpub.ru/jour/article/view/648</self-uri><abstract><sec><title> Актуальность</title><p> Актуальность. В базисной терапии ХСН одно из ведущих мест занимает пульсурежающая терапия. В то время как целевые значения ЧСС при синусовом ритме установлены, единого мнения о том, какая ЧСС является идеальной у пациентов с ХСН на фоне фибрилляции предсердий (ФП), нет. Таким образом, исследование прогноза у пациентов с ХСН и ФП в зависимости от достигнутой ЧСС актуальны.</p></sec><sec><title>Цель</title><p>Цель. Проанализировать общую смертность и установить стратификационные риски смертельных исходов у пациентов с ХСН и ФП в зависимости от формы ФП, ФК ХСН и наличия тахикардии. Материал и методы. Проведено проспективное когортное исследование пациентов с ХСН, которые в течение года наблюдались в Городском центре лечения ХСН (n=591), из них 280 (47,4%) пациентов были с ФП, 311 (52,6%) – без ФП.</p></sec><sec><title>Результаты</title><p>Результаты. Через год наблюдения среди пациентов с ФП постоянная, персистирующая и пароксизмальная формы ФП были зарегистрированы в 55,4, 36,4 и 8,2% случаев соответственно. У 12,2% пациентов ФП была диагностирована впервые. По ФК ХСН, ФВ ЛЖ, баллам по Шкале оценки клинического состояния (ШОКС) группа с постоянной ФП была тяжелее, чем без ФП. Достоверно увеличивалась смертность пациентов с тахикардией в зависимости от увеличения ФК ХСН с I–II до III–IV: в группе без ФП – с 3,6 до 14,9% случаев (р=0,04), а в группе с пароксизмальной и персистирующей ФП – с 6,7 до 25,9% (р=0,043). Наличие тахикардии увеличивало риск смерти на 61%, а переход в более тяжелый ФК – в 4,9 раза. С каждым увеличением показателя ШОКС на 1 балл смертность в представленной выборке увеличивалась на 16%.</p></sec><sec><title>Заключение</title><p>Заключение. ЧСС не является самостоятельным предиктором смерти, но в сочетании с III–IV ФК ХСН тахикардия значительно ухудшает прогноз.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Actuality</title><p>Actuality. In the basic therapy of CHF, drugs that reduce the pulse is one of the leading places. Target values of heart rate with sinus rhythm are established. Tere is still no consensus as to which heart rate is ideal in patients with CHF on the background of the rhythm of atrial fbrillation (AF). Te study of the prognosis in patients with CHF and AF depending on the achieved heart rate is relevant.</p></sec><sec><title>Objective</title><p>Objective. To analyze the overall mortality and establish the stratifcation risks of death in patients with CHF and AF depending on the form of AF, functional class of CHF and the presence of tachycardia.</p></sec><sec><title>Material and methods</title><p>Material and methods. A prospective cohort study was conducted in a group of patients with CHF who were observed at the City Center for CHF treatment (n = 591) during the year. Of these, 47.4% of patients had CHF and AF (n = 280) and 52.6% of patients with CHF without AF (n = 311).</p></sec><sec><title>Results</title><p>Results. In a year, a permanent AF registered among patients with CHF and AF in 55.4%, persistent – in 36.4%, and paroxysmal – in 8.2% of cases. In 12.2% of patients, the diagnosis of AF was frst diagnosed. According to functional class of CHF, LVEF, assessment of clinical assessment scale, the group with a permanent AF was signifcantly heavier than without AF. Te mortality of patients with tachycardia signifcantly increased as a function of the increase in CHF from I–II to III–IV class: from 3.6% to 14.9% in the group without AF (p=0.04), and in the group with paroxysmal and persistent AF from 6.7% to 25.9% (p = 0.043). Te presence of tachycardia increases the risk of death by 61%, and the transition to a heavier functional class is 4.9 times. With each increase in the clinical assessment scale exponent by 1 point, the mortality rate in the sample is increased by 16%.</p></sec><sec><title>Conclusion</title><p>Conclusion. Heart rate is not an independent predictor of death, but in combination with functional class III–IV CHF tachycardia signifcantly worsens the prognosis.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая сердечная недостаточность</kwd><kwd>фибрилляция предсердий</kwd><kwd>общая смертность</kwd><kwd>лечение</kwd><kwd>бета-блокаторы</kwd><kwd>тахикардия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic heart failure</kwd><kwd>atrial fbrillation</kwd><kwd>all-cause mortality</kwd><kwd>treatment</kwd><kwd>beta-blockers</kwd><kwd>tachycardia</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П., Коротеев А. В., Мареев Ю. В., Овчинников А. Г. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр) . Утверждены на Конгрессе ОССН 7 декабря 2012 года, на Правлении ОССН 31 марта 2013 и Конгрессе РКО 25 сентября 2013 года. Журнал Сердечная Недостаточность. 2013;14(7):379- 472. DOI: 10.18087/rhf.2013.7.1860</mixed-citation><mixed-citation xml:lang="en">Mareev V. Yu., Ageev F. T., Arutyunov G. P., Koroteev A. V., Mareev Yu. V., Ovchinnikov A. G. et al. SEHF, RSC and RSMSIM national guidelines on CHF diagnostics and treatment (fourth revision) Approved at the SEHF Congress on December 7, 2012, at the SEHF Board of Directors meeting on March 31, 2013, and at the RSC Congress on September 25, 2013. Russian Heart Failure Journal. 2013;14 (7):379–472. [Russian]. DOI: 10.18087/rhf.2013.7.1860</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Поляков Д.С., Фомин И.В., Валикулова Ф.Ю., Вайсберг А.Р., Краием Н., Бадин Ю.В. и др. Эпидемиологическая программа ЭПОХА-ХСН: Декомпенсация хронической сердечной недостаточности в реальной клинической практике (ЭПОХА-ДХСН). Журнал Сердечная Недостаточность. 2016;17(5):299–305. DOI: 10.18087/rhf.2016.5.2239</mixed-citation><mixed-citation xml:lang="en">Polyakov D.S., Fomin I.V., Valikulova F.Yu., Vaisberg A.R., Kraiem N., Badin Yu.V. et al. Te EPOCH-CHF epidemiological program: decompensated chronic heart failure in real-life clinical practice (EPOCH-D–CHF). Russian Heart Failure Journal. 2016;17 (5):299– 305. [Russian]. DOI: 10.18087/rhf.2016.5.2239</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Мареев В.Ю., Фомин И.В., Агеев Ф.Т., Беграмбекова Ю.Л., Васюк Ю.А., Гарганеева А.А. и др. Клинические рекомендации ОССН – РКО – РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(S6):8- 164. DOI: 10.18087/cardio.2475</mixed-citation><mixed-citation xml:lang="en">Mareev V. Yu., Fomin I. V., Ageev F. T., Begrambekova Yu. L., Vasyuk Yu.A., Garganeeva A.A. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientifc Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58 (S6):8–164. [Russian]. DOI: 10.18087/cardio.2475</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JGF et al. Efcacy of β blockers in patients with heart failure plus atrial fbrillation: an individual-patient data meta-analysis. Te Lancet. 2014;384(9961):2235–43. DOI: 10.1016/S0140-6736(14)61373-8</mixed-citation><mixed-citation xml:lang="en">Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JGF et al. Efcacy of β blockers in patients with heart failure plus atrial fbrillation: an individual-patient data meta-analysis. Te Lancet. 2014;384(9961):2235–43. DOI: 10.1016/S0140-6736(14)61373-8</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">McMurray J, Køber L, Robertson M, Dargie H, Colucci W, LopezSendon J et al. Antiarrhythmic eﬀect of carvedilol afer acute myocardial infarction. Journal of the American College of Cardiology. 2005;45 (4):525–30. DOI: 10.1016/j.jacc.2004.09.076</mixed-citation><mixed-citation xml:lang="en">McMurray J, Køber L, Robertson M, Dargie H, Colucci W, LopezSendon J et al. Antiarrhythmic eﬀect of carvedilol afer acute myocardial infarction. Journal of the American College of Cardiology. 2005;45 (4):525–30. DOI: 10.1016/j.jacc.2004.09.076</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Pedersen OD, Bagger H, Køber L, Torp-Pedersen C. Trandolapril Reduces the Incidence of Atrial Fibrillation Afer Acute Myocardial Infarction in Patients with Lef Ventricular Dysfunction. Circulation. 1999;100(4):376–80. DOI: 10.1161/01.CIR.100.4.376</mixed-citation><mixed-citation xml:lang="en">Pedersen OD, Bagger H, Køber L, Torp-Pedersen C. Trandolapril Reduces the Incidence of Atrial Fibrillation Afer Acute Myocardial Infarction in Patients with Lef Ventricular Dysfunction. Circulation. 1999;100(4):376–80. DOI: 10.1161/01.CIR.100.4.376</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ducharme A, Swedberg K, Pfeﬀer MA, Cohen-Solal A, Granger CB, Maggioni AP et al. Prevention of atrial fbrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. American Heart Journal. 2006;152(1):86–92. PMID: 16838426</mixed-citation><mixed-citation xml:lang="en">Ducharme A, Swedberg K, Pfeﬀer MA, Cohen-Solal A, Granger CB, Maggioni AP et al. Prevention of atrial fbrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. American Heart Journal. 2006;152(1):86–92. PMID: 16838426</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Swedberg K, Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Shi H et al. Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure. Journal of the American College of Cardiology. 2012;59(18):1598–603. DOI: 10.1016/j.jacc.2011.11.063</mixed-citation><mixed-citation xml:lang="en">Swedberg K, Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Shi H et al. Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure. Journal of the American College of Cardiology. 2012;59(18):1598–603. DOI: 10.1016/j.jacc.2011.11.063</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">McAlister FA. Meta-analysis: β-blocker dose, heart rate reduction, and death in patients with heart failure. Annals of Internal Medicine. 2009;150(11):784–94. DOI: 10.7326/0003-4819-150-11-200906020-00006</mixed-citation><mixed-citation xml:lang="en">McAlister FA. Meta-analysis: β-blocker dose, heart rate reduction, and death in patients with heart failure. Annals of Internal Medicine. 2009;150(11):784–94. DOI: 10.7326/0003-4819-150-11-200906020-00006</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Böhm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, LopezSendon J et al. Heart rate at baseline inﬂuences the eﬀect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology. 2013;102(1):11–22. DOI: 10.1007/s00392-012-0467-8</mixed-citation><mixed-citation xml:lang="en">Böhm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, LopezSendon J et al. Heart rate at baseline inﬂuences the eﬀect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology. 2013;102(1):11–22. DOI: 10.1007/s00392-012-0467-8</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of Randomized Controlled Trials on the Eﬀect of Magnitude of Heart Rate Reduction on Clinical Outcomes in Patients with Systolic Chronic Heart Failure Receiving Beta-Blockers. Te American Journal of Cardiology. 2008;101(6):865–9. DOI: 10.1016/j.amjcard.2007.11.023</mixed-citation><mixed-citation xml:lang="en">Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of Randomized Controlled Trials on the Eﬀect of Magnitude of Heart Rate Reduction on Clinical Outcomes in Patients with Systolic Chronic Heart Failure Receiving Beta-Blockers. Te American Journal of Cardiology. 2008;101(6):865–9. DOI: 10.1016/j.amjcard.2007.11.023</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Fiuzat M, Wojdyla D, Pina I, Adams K, Whellan D, O’Connor CM. Heart Rate or Beta-Blocker Dose? Association with Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction. JACC: Heart Failure. 2016;4(2):109–15. DOI: 10.1016/j.jchf.2015.09.002</mixed-citation><mixed-citation xml:lang="en">Fiuzat M, Wojdyla D, Pina I, Adams K, Whellan D, O’Connor CM. Heart Rate or Beta-Blocker Dose? Association with Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction. JACC: Heart Failure. 2016;4(2):109–15. DOI: 10.1016/j.jchf.2015.09.002</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Cullington D, Goode KM, Clark AL, Cleland JGF. Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target? European Journal of Heart Failure. 2012;14(7):737–47. DOI: 10.1093/eurjhf/hfs060</mixed-citation><mixed-citation xml:lang="en">Cullington D, Goode KM, Clark AL, Cleland JGF. Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target? European Journal of Heart Failure. 2012;14(7):737–47. DOI: 10.1093/eurjhf/hfs060</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fbrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893–962. DOI: 10.1093/eurheartj/ehw210</mixed-citation><mixed-citation xml:lang="en">Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fbrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893–962. DOI: 10.1093/eurheartj/ehw210</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128(16):e240-327. DOI: 10.1161/CIR.0b013e31829e8776</mixed-citation><mixed-citation xml:lang="en">Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128(16):e240-327. DOI: 10.1161/CIR.0b013e31829e8776</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Te Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129–200. DOI: 10.1093/eurheartj/ehw128</mixed-citation><mixed-citation xml:lang="en">Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Te Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129–200. DOI: 10.1093/eurheartj/ehw128</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">O’Meara E, Solomon S, McMurray JJ, Pfeﬀer M, Yusuf S, Michelson E et al. Eﬀect of candesartan on New York Heart Association functional classResults of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal. 2004;25(21):1920–6. DOI: 10.1016/j.ehj.2004.07.025</mixed-citation><mixed-citation xml:lang="en">O’Meara E, Solomon S, McMurray JJ, Pfeﬀer M, Yusuf S, Michelson E et al. Eﬀect of candesartan on New York Heart Association functional classResults of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal. 2004;25(21):1920–6. DOI: 10.1016/j.ehj.2004.07.025</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Козиолова Н. А., Никонова Ю. Н., Шилова Я. Э., Агафонов А. В., Полянская Е. А. Характеристика хронической сердечной недостаточности на фоне перманентной формы фибрилляции предсердий. Журнал Сердечная Недостаточность. 2013;14(1):14-21. DOI: 10.18087/rhf.2013.1.1806</mixed-citation><mixed-citation xml:lang="en">Koziolova N. A., Nikonova Yu. N., Shilova Ya. E., Agafonov A. V., Polianskaya E. A. Description of chronic heart failure against the background of permanent atrial fbrillation. Russian Heart Failure Journal. 2013;14 (1):14–21. [Russian]. DOI: 10.18087/rhf.2013.1.1806</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Tihalolipavan S, Morin DP. Atrial Fibrillation and Heart Failure: Update 2015. Progress in Cardiovascular Diseases. 2015;58(2):126– 35. DOI: 10.1016/j.pcad.2015.07.004</mixed-citation><mixed-citation xml:lang="en">Tihalolipavan S, Morin DP. Atrial Fibrillation and Heart Failure: Update 2015. Progress in Cardiovascular Diseases. 2015;58(2):126– 35. DOI: 10.1016/j.pcad.2015.07.004</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Fiuzat M, Wojdyla D, Kitzman D, Fleg J, Keteyian SJ, Kraus WE et al. Relationship of Beta-Blocker Dose with Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction. Journal of the American College of Cardiology. 2012;60(3):208–15. DOI: 10.1016/j.jacc.2012.03.023</mixed-citation><mixed-citation xml:lang="en">Fiuzat M, Wojdyla D, Kitzman D, Fleg J, Keteyian SJ, Kraus WE et al. Relationship of Beta-Blocker Dose with Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction. Journal of the American College of Cardiology. 2012;60(3):208–15. DOI: 10.1016/j.jacc.2012.03.023</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH et al. Dosing of Beta-Blocker Terapy Before, During, and Afer Hospitalization for Heart Failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). Te American Journal of Cardiology. 2008;102(11):1524–9. DOI: 10.1016/j.amjcard.2008.07.045</mixed-citation><mixed-citation xml:lang="en">Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH et al. Dosing of Beta-Blocker Terapy Before, During, and Afer Hospitalization for Heart Failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). Te American Journal of Cardiology. 2008;102(11):1524–9. DOI: 10.1016/j.amjcard.2008.07.045</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Dierckx R, Cleland JGF, Parsons S, Putzu P, Pellicori P, Dicken B et al. Prescribing Paterns to Optimize Heart Rate: analysis of 1,000 consecutive outpatient appointments to a single heart failure clinic over a 6-month period. JACC: Heart Failure. 2015;3(3):224–30. DOI: 10.1016/j.jchf.2014.11.003</mixed-citation><mixed-citation xml:lang="en">Dierckx R, Cleland JGF, Parsons S, Putzu P, Pellicori P, Dicken B et al. Prescribing Paterns to Optimize Heart Rate: analysis of 1,000 consecutive outpatient appointments to a single heart failure clinic over a 6-month period. JACC: Heart Failure. 2015;3(3):224–30. DOI: 10.1016/j.jchf.2014.11.003</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Wikstrand J, Hjalmarson Å ke, Waagstein F, Fagerberg B jörn, Goldstein S, Kjekshus J et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF) . Journal of the American College of Cardiology. 2002;40(3):491–8. DOI: 10.1016/S0735-1097(02)01970-8</mixed-citation><mixed-citation xml:lang="en">Wikstrand J, Hjalmarson Å ke, Waagstein F, Fagerberg B jörn, Goldstein S, Kjekshus J et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF) . Journal of the American College of Cardiology. 2002;40(3):491–8. DOI: 10.1016/S0735-1097(02)01970-8</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Виноградова Н. Г., Фомин И. В., Поляков Д. С., Жиркова М. М., Тюрин А. А., Крылова А. Н. и др. Эффективность контроля гемодинамических показателей и прогноз пациентов с хронической сердечной недостаточностью и фибрилляцией предсердий в условиях реальной клинической практики. Кардиология. 2018;58(S8):43-53. DOI: 10.18087/cardio.2440</mixed-citation><mixed-citation xml:lang="en">Vinogradova N. G., Fomin I. V., Polyakov D. S., Zhirkova M. M., Tyurin A. A., Krylova A. N. et al. Eﬀectiveness of control over hemodynamic indexes and prognosis for patients with CHF and atrial fbrillation in real-life clinical practice. Kardiologiia. 2018,58(S8):43–53. [Russian]. DOI: 10.18087/cardio.2440</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Laskey WK, Alomari I, Cox M, Schulte PJ, Zhao X, Hernandez AF et al. Heart Rate at Hospital Discharge in Patients with Heart Failure Is Associated With Mortality and Rehospitalization. Journal of the American Heart Association. 2015;4(4):e001626–e001626. DOI: 10.1161/JAHA.114.001626</mixed-citation><mixed-citation xml:lang="en">Laskey WK, Alomari I, Cox M, Schulte PJ, Zhao X, Hernandez AF et al. Heart Rate at Hospital Discharge in Patients with Heart Failure Is Associated With Mortality and Rehospitalization. Journal of the American Heart Association. 2015;4(4):e001626–e001626. DOI: 10.1161/JAHA.114.001626</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Li S-J, Sartipy U, Lund LH, Dahlström U, Adiels M, Petzold M et al. Prognostic Signifcance of Resting Heart Rate and Use of β-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients with Heart Failure and Reduced Ejection FractionCLINICAL PERSPECTIVE: Findings From the Swedish Heart Failure Registry. Circulation: Heart Failure. 2015;8(5):871–9. DOI: 10.1161/CIRCHEARTFAILURE.115.002285</mixed-citation><mixed-citation xml:lang="en">Li S-J, Sartipy U, Lund LH, Dahlström U, Adiels M, Petzold M et al. Prognostic Signifcance of Resting Heart Rate and Use of β-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients with Heart Failure and Reduced Ejection FractionCLINICAL PERSPECTIVE: Findings From the Swedish Heart Failure Registry. Circulation: Heart Failure. 2015;8(5):871–9. DOI: 10.1161/CIRCHEARTFAILURE.115.002285</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Simpson J, Castagno D, Doughty RN, Poppe KK, Earle N, Squire I et al. Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fbrillation? Results from the MAGGIC meta-analysis. European Journal of Heart Failure. 2015;17(11):1182–91. DOI: 10.1002/ejhf.346</mixed-citation><mixed-citation xml:lang="en">Simpson J, Castagno D, Doughty RN, Poppe KK, Earle N, Squire I et al. Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fbrillation? Results from the MAGGIC meta-analysis. European Journal of Heart Failure. 2015;17(11):1182–91. DOI: 10.1002/ejhf.346</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Rienstra M, Damman K, Mulder BA, Van Gelder IC, McMurray JJV, Van Veldhuisen DJ. Beta-Blockers and Outcome in Heart Failure and Atrial Fibrillation. JACC: Heart Failure. 2013;1(1):21–8. DOI: 10.1016/j.jchf.2012.09.002</mixed-citation><mixed-citation xml:lang="en">Rienstra M, Damman K, Mulder BA, Van Gelder IC, McMurray JJV, Van Veldhuisen DJ. Beta-Blockers and Outcome in Heart Failure and Atrial Fibrillation. JACC: Heart Failure. 2013;1(1):21–8. DOI: 10.1016/j.jchf.2012.09.002</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Cullington D, Goode KM, Zhang J, Cleland JGF, Clark AL. Is heart rate important for patients with heart failure in atrial fbrillation? JACC. Heart failure. 2014;2(3):213–20. DOI: 10.1016/j.jchf.2014.01.005</mixed-citation><mixed-citation xml:lang="en">Cullington D, Goode KM, Zhang J, Cleland JGF, Clark AL. Is heart rate important for patients with heart failure in atrial fbrillation? JACC. Heart failure. 2014;2(3):213–20. DOI: 10.1016/j.jchf.2014.01.005</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Mareev Y, Cleland JGF. Should β-blockers be used in patients with heart failure and atrial fbrillation? Clinical Terapeutics. 2015;37 (10):2215–24. DOI: 10.1016/j.clinthera.2015.08.017</mixed-citation><mixed-citation xml:lang="en">Mareev Y, Cleland JGF. Should β-blockers be used in patients with heart failure and atrial fbrillation? Clinical Terapeutics. 2015;37 (10):2215–24. DOI: 10.1016/j.clinthera.2015.08.017</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
